Skip to main content
Top
Published in: Supportive Care in Cancer 9/2013

01-09-2013 | Original Article

A prospective study of characteristics and outcomes of bacteremia in patients with solid organ or hematologic malignancies

Authors: George Samonis, Konstantinos Z. Vardakas, Sofia Maraki, Giannoula S. Tansarli, Dimitra Dimopoulou, Diamantis P. Kofteridis, Angeliki M. Andrianaki, Matthew E. Falagas

Published in: Supportive Care in Cancer | Issue 9/2013

Login to get access

Abstract

Objective

To study the epidemiology and outcomes of bacteremia in patients with hematologic or solid organ malignancies cared for at the University Hospital of Heraklion, Greece.

Methods

This prospective study was conducted during a 4-year period (2007–2011). Patients with bacterial and fungal blood stream infections were followed until discharge. Mortality was the primary outcome, while duration of hospitalization, relapses, time to relapse, and defervescence were the secondary outcomes.

Results

Ninety-nine patients with neoplasia (104 episodes) were included. Bacteremia developed mainly in patients with hematologic malignancies (56 %). Secondary bacteremias due to respiratory and urinary tract infections were most commonly identified. Gram-negative bacteria were the predominantly isolated pathogens (65 %); Pseudomonas spp. was the most common cause (19 %), followed closely by E. coli (18 %) and Klebsiella pneumoniae (17 %). In-hospital mortality was 26.2 %. No differences in mortality were seen among patients in different subgroups according to isolated bacteria (according to Gram’s stain, species, or number of isolated bacteria in positive cultures), hematologic or solid organ malignancy, neutropenia, and primary or secondary bacteremia. However, patients with bacteremia due to extensively drug resistant bacteria had higher mortality than patients with bacteremia due to multidrug resistant or susceptible pathogens. Patients required a prolonged period of hospitalization (21.8 ± 14.9 days), which was complicated with relapses or reinfections in another body site in 27 % of them.

Conclusion

Gram-negative bacteria were the predominantly isolated pathogens from patients with cancer in our population. The overall mortality remains high.
Literature
1.
2.
go back to reference Rafailidis PI, Kakisi OK, Vardakas K, Falagas ME (2007) Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer 109(11):2182–2189CrossRef Rafailidis PI, Kakisi OK, Vardakas K, Falagas ME (2007) Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer 109(11):2182–2189CrossRef
3.
go back to reference Bliziotis IA, Michalopoulos A, Kasiakou SK et al (2005) Ciprofloxacin vs. an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials. Mayo Clin Proc 80(9):1146–1156CrossRef Bliziotis IA, Michalopoulos A, Kasiakou SK et al (2005) Ciprofloxacin vs. an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials. Mayo Clin Proc 80(9):1146–1156CrossRef
4.
go back to reference Samonis G, Koutsounaki E, Karageorgopoulos DE et al (2012) Empirical therapy with ceftazidime combined with levofloxacin or once-daily Amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study. Eur J Clin Microbiol Infect Dis 31(7):1389–1398CrossRef Samonis G, Koutsounaki E, Karageorgopoulos DE et al (2012) Empirical therapy with ceftazidime combined with levofloxacin or once-daily Amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study. Eur J Clin Microbiol Infect Dis 31(7):1389–1398CrossRef
5.
go back to reference Vardakas KZ, Samonis G, Chrysanthopoulou SA, Bliziotis IA, Falagas ME (2005) Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomized controlled trials. Lancet Infect Dis 5(7):431–439CrossRef Vardakas KZ, Samonis G, Chrysanthopoulou SA, Bliziotis IA, Falagas ME (2005) Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomized controlled trials. Lancet Infect Dis 5(7):431–439CrossRef
6.
go back to reference Norgaard M, Larsson H, Pedersen G, Schonheyder HC, Sorensen HT (2006) Hematological malignancies—a predictor of a poor outcome in patients with bacteremia. J Infect 53(3):190–198CrossRef Norgaard M, Larsson H, Pedersen G, Schonheyder HC, Sorensen HT (2006) Hematological malignancies—a predictor of a poor outcome in patients with bacteremia. J Infect 53(3):190–198CrossRef
7.
go back to reference Klastersky J (1998) Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother 41(Suppl D):13–24CrossRef Klastersky J (1998) Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother 41(Suppl D):13–24CrossRef
8.
go back to reference Klastersky J, Ameye L, Maertens J et al (2007) Bacteremia in febrile neutropenic cancer patients. Int J Antimicrob Agents 30(Suppl 1):S51–S59CrossRef Klastersky J, Ameye L, Maertens J et al (2007) Bacteremia in febrile neutropenic cancer patients. Int J Antimicrob Agents 30(Suppl 1):S51–S59CrossRef
9.
go back to reference Viscoli C, Cometta A, Kern WV et al (2006) Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. Clin Microbiol Infect 12(3):212–216CrossRef Viscoli C, Cometta A, Kern WV et al (2006) Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. Clin Microbiol Infect 12(3):212–216CrossRef
10.
go back to reference Anatoliotaki M, Valatas V, Mantadakis E et al (2004) Bloodstream infections in patients with solid tumors: associated factors, microbial spectrum, and outcome. Infection 32(2):65–71CrossRef Anatoliotaki M, Valatas V, Mantadakis E et al (2004) Bloodstream infections in patients with solid tumors: associated factors, microbial spectrum, and outcome. Infection 32(2):65–71CrossRef
11.
go back to reference Fassas A, Papageorgiou T, Kontodimou A, Proya E, Hadjikyrkou M, Anagnostopoulos A (1989) Imipenem/cilastatin as initial single-agent therapy for infections in cancer patients with neutropenia. J Chemother 1(4 Suppl):1295–1297PubMed Fassas A, Papageorgiou T, Kontodimou A, Proya E, Hadjikyrkou M, Anagnostopoulos A (1989) Imipenem/cilastatin as initial single-agent therapy for infections in cancer patients with neutropenia. J Chemother 1(4 Suppl):1295–1297PubMed
12.
go back to reference Roilides E, Sidi V, Gompakis N, Tsivitanidou M, Katsaveli A, Koliouskas D (1998) Patterns and outcome of septicemia in neutropenic children with cancer in a Greek hospital. Infection 26(3):189–191CrossRef Roilides E, Sidi V, Gompakis N, Tsivitanidou M, Katsaveli A, Koliouskas D (1998) Patterns and outcome of septicemia in neutropenic children with cancer in a Greek hospital. Infection 26(3):189–191CrossRef
13.
go back to reference Who (2010) Who: WHO guidelines on drawing blood: best practices in phlebotomy Who (2010) Who: WHO guidelines on drawing blood: best practices in phlebotomy
14.
go back to reference Hsieh MM, Everhart JE, Byrd-Holt DD, Tisdale JF, Rodgers GP (2007) Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med 146(7):486–492CrossRef Hsieh MM, Everhart JE, Byrd-Holt DD, Tisdale JF, Rodgers GP (2007) Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med 146(7):486–492CrossRef
15.
go back to reference Institute Nc (2003) Common toxicity criteria for adverse events. In: Cancer therapeutics evaluation program. Bethesda Institute Nc (2003) Common toxicity criteria for adverse events. In: Cancer therapeutics evaluation program. Bethesda
16.
go back to reference Magiorakos AP, Srinivasan A, Carey RB et al (2012) Multidrug-resistant, extensively drug-resistant, and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18(3):268–281CrossRef Magiorakos AP, Srinivasan A, Carey RB et al (2012) Multidrug-resistant, extensively drug-resistant, and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18(3):268–281CrossRef
17.
go back to reference Arvanitidou M, Katikaridou E, Douboyas J, Tsakris A (2005) Epidemiological characteristics of nosocomial bacteremias among ICU and non-ICU patients in a tertiary-care hospital in Greece. J Hosp Infect 59(1):70–72CrossRef Arvanitidou M, Katikaridou E, Douboyas J, Tsakris A (2005) Epidemiological characteristics of nosocomial bacteremias among ICU and non-ICU patients in a tertiary-care hospital in Greece. J Hosp Infect 59(1):70–72CrossRef
18.
go back to reference Hadziyannis AS, Stephanou I, Dimarogona K et al (2004) Blood culture results during the period 1995–2002 in a Greek tertiary care hospital. Clin Microbiol Infect 10(7):667–670CrossRef Hadziyannis AS, Stephanou I, Dimarogona K et al (2004) Blood culture results during the period 1995–2002 in a Greek tertiary care hospital. Clin Microbiol Infect 10(7):667–670CrossRef
19.
go back to reference Paragioudaki M, Stamouli V, Kolonitsiou F, Anastassiou ED, Dimitracopoulos G, Spiliopoulou I (2004) Intravenous catheter infections associated with bacteremia: a 2-year study in a university hospital. Clin Microbiol Infect 10(5):431–435CrossRef Paragioudaki M, Stamouli V, Kolonitsiou F, Anastassiou ED, Dimitracopoulos G, Spiliopoulou I (2004) Intravenous catheter infections associated with bacteremia: a 2-year study in a university hospital. Clin Microbiol Infect 10(5):431–435CrossRef
20.
go back to reference Tsitsopoulos PP, Iosifidis E, Antachopoulos C et al (2010) A 5-year epidemiological study of nosocomial bloodstream infections in a neurosurgery department. Infect Control Hosp Epidemiol 31(4):414–417CrossRef Tsitsopoulos PP, Iosifidis E, Antachopoulos C et al (2010) A 5-year epidemiological study of nosocomial bloodstream infections in a neurosurgery department. Infect Control Hosp Epidemiol 31(4):414–417CrossRef
21.
go back to reference Kang CI, Song JH, Chung DR et al (2012) Bloodstream infections in adult patients with cancer: clinical features and pathogenic significance of Staphylococcus aureus bacteremia. Support Care Cancer 10:2371–8CrossRef Kang CI, Song JH, Chung DR et al (2012) Bloodstream infections in adult patients with cancer: clinical features and pathogenic significance of Staphylococcus aureus bacteremia. Support Care Cancer 10:2371–8CrossRef
22.
go back to reference Singer C, Kaplan MH, Armstrong D (1977) Bacteremia and fungemia complicating neoplastic disease. A study of 364 cases. Am J Med 62(5):731–742CrossRef Singer C, Kaplan MH, Armstrong D (1977) Bacteremia and fungemia complicating neoplastic disease. A study of 364 cases. Am J Med 62(5):731–742CrossRef
23.
go back to reference Coullioud D, Van Der Auwera P, Viot M, Lasset C (1993) Prospective multicentric study of the etiology of 1,051 bacteremic episodes in 782 cancer patients. CEMIC (French-Belgian Study Club of Infectious Diseases in Cancer). Support Care Cancer 1(1):34–46CrossRef Coullioud D, Van Der Auwera P, Viot M, Lasset C (1993) Prospective multicentric study of the etiology of 1,051 bacteremic episodes in 782 cancer patients. CEMIC (French-Belgian Study Club of Infectious Diseases in Cancer). Support Care Cancer 1(1):34–46CrossRef
24.
go back to reference Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, Granena A, Gudiol F (1996) Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis 15(4):291–296CrossRef Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, Granena A, Gudiol F (1996) Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis 15(4):291–296CrossRef
25.
go back to reference Spanik S, Sufliarsky J, Mardiak J et al (1998) Predictors of mortality in bacteremic cancer patients: retrospective analysis of 64 deaths occurring among 262 bacteremic episodes. Support Care Cancer 6(3):291–294CrossRef Spanik S, Sufliarsky J, Mardiak J et al (1998) Predictors of mortality in bacteremic cancer patients: retrospective analysis of 64 deaths occurring among 262 bacteremic episodes. Support Care Cancer 6(3):291–294CrossRef
26.
go back to reference Escande MC, Herbrecht R (1998) Prospective study of bacteremia in cancer patients. Results of a French multicentre study. Support Care Cancer 6(3):273–280CrossRef Escande MC, Herbrecht R (1998) Prospective study of bacteremia in cancer patients. Results of a French multicentre study. Support Care Cancer 6(3):273–280CrossRef
27.
go back to reference Velasco E, Thuler LC, Martins CA, Nucci M, Dias LM, Goncalves VM (2000) Epidemiology of bloodstream infections at a cancer center. Sao Paulo Med J 118(5):131–138CrossRef Velasco E, Thuler LC, Martins CA, Nucci M, Dias LM, Goncalves VM (2000) Epidemiology of bloodstream infections at a cancer center. Sao Paulo Med J 118(5):131–138CrossRef
28.
go back to reference Whimbey E, Kiehn TE, Brannon P, Blevins A, Armstrong D (1987) Bacteremia and fungemia in patients with neoplastic disease. Am J Med 82(4):723–730CrossRef Whimbey E, Kiehn TE, Brannon P, Blevins A, Armstrong D (1987) Bacteremia and fungemia in patients with neoplastic disease. Am J Med 82(4):723–730CrossRef
29.
go back to reference Lowder JN, Lazarus HM, Herzig RH (1982) Bacteremias and fungemias in oncologic patients with central venous catheters: changing spectrum of infection. Arch Intern Med 142(8):1456–1459CrossRef Lowder JN, Lazarus HM, Herzig RH (1982) Bacteremias and fungemias in oncologic patients with central venous catheters: changing spectrum of infection. Arch Intern Med 142(8):1456–1459CrossRef
30.
go back to reference Raad I, Narro J, Khan A, Tarrand J, Vartivarian S, Bodey GP (1992) Serious complications of vascular catheter-related Staphylococcus aureus bacteremia in cancer patients. Eur J Clin Microbiol Infect Dis 11(8):675–682CrossRef Raad I, Narro J, Khan A, Tarrand J, Vartivarian S, Bodey GP (1992) Serious complications of vascular catheter-related Staphylococcus aureus bacteremia in cancer patients. Eur J Clin Microbiol Infect Dis 11(8):675–682CrossRef
31.
go back to reference Weinstein MP, Towns ML, Quartey SM et al (1997) The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 24(4):584–602CrossRef Weinstein MP, Towns ML, Quartey SM et al (1997) The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 24(4):584–602CrossRef
32.
go back to reference Geerdes HF, Ziegler D, Lode H et al (1992) Septicemia in 980 patients at a university hospital in Berlin: prospective studies during 4 selected years between 1979 and 1989. Clin Infect Dis 15(6):991–1002CrossRef Geerdes HF, Ziegler D, Lode H et al (1992) Septicemia in 980 patients at a university hospital in Berlin: prospective studies during 4 selected years between 1979 and 1989. Clin Infect Dis 15(6):991–1002CrossRef
33.
go back to reference Celkan T, Ozkan A, Apak H et al (2002) Bacteremia in childhood cancer. J Trop Pediatr 48(6):373–377CrossRef Celkan T, Ozkan A, Apak H et al (2002) Bacteremia in childhood cancer. J Trop Pediatr 48(6):373–377CrossRef
34.
go back to reference Cherif H, Kronvall G, Bjorkholm M, Kalin M (2003) Bacteremia in hospitalized patients with malignant blood disorders: a retrospective study of causative agents and their resistance profiles during a 14-year period without antibacterial prophylaxis. Hematol J 4(6):420–426CrossRef Cherif H, Kronvall G, Bjorkholm M, Kalin M (2003) Bacteremia in hospitalized patients with malignant blood disorders: a retrospective study of causative agents and their resistance profiles during a 14-year period without antibacterial prophylaxis. Hematol J 4(6):420–426CrossRef
35.
go back to reference Joo EJ, Kang CI, Ha YE et al (2011) Clinical predictors of Pseudomonas aeruginosa bacteremia among Gram-negative bacterial infections in non-neutropenic patients with solid tumor. J Infect 63(3):207–214CrossRef Joo EJ, Kang CI, Ha YE et al (2011) Clinical predictors of Pseudomonas aeruginosa bacteremia among Gram-negative bacterial infections in non-neutropenic patients with solid tumor. J Infect 63(3):207–214CrossRef
36.
go back to reference Wang SS, Lee NY, Hsueh PR et al (2011) Clinical manifestations and prognostic factors in cancer patients with bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae. J Microbiol Immunol Infect 44(4):282–288CrossRef Wang SS, Lee NY, Hsueh PR et al (2011) Clinical manifestations and prognostic factors in cancer patients with bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae. J Microbiol Immunol Infect 44(4):282–288CrossRef
37.
go back to reference Vardakas KZ, Rafailidis PI, Konstantelias AA, Falagas ME (2012) Predictors of mortality in patients with infections due to multidrug resistant Gram-negative bacteria: the study, the patient, the bug, or the drug? J Infect 66(5):401–14CrossRef Vardakas KZ, Rafailidis PI, Konstantelias AA, Falagas ME (2012) Predictors of mortality in patients with infections due to multidrug resistant Gram-negative bacteria: the study, the patient, the bug, or the drug? J Infect 66(5):401–14CrossRef
Metadata
Title
A prospective study of characteristics and outcomes of bacteremia in patients with solid organ or hematologic malignancies
Authors
George Samonis
Konstantinos Z. Vardakas
Sofia Maraki
Giannoula S. Tansarli
Dimitra Dimopoulou
Diamantis P. Kofteridis
Angeliki M. Andrianaki
Matthew E. Falagas
Publication date
01-09-2013
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 9/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-1816-5

Other articles of this Issue 9/2013

Supportive Care in Cancer 9/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine